Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 264

Results For "IMI"

4151 News Found

Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules
Drug Approval | January 16, 2023

Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India


Granules India’s Gagillapur facility completes USFDA inspection
Drug Approval | January 16, 2023

Granules India’s Gagillapur facility completes USFDA inspection

The company will respond to these observations within the stipulated time period.


Quantumzyme and BEC Chemicals to collaborate for green chemistry development
News | January 14, 2023

Quantumzyme and BEC Chemicals to collaborate for green chemistry development

This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.


135 crore footfalls registered at AB-HWCs
Policy | January 13, 2023

135 crore footfalls registered at AB-HWCs

Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs


Dozee partners British International Investment to transform public healthcare in India
Healthcare | January 13, 2023

Dozee partners British International Investment to transform public healthcare in India

The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards


Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets
Drug Approval | January 13, 2023

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults


USFDA inspects Piramal Pharma Lexington facility
Drug Approval | January 12, 2023

USFDA inspects Piramal Pharma Lexington facility

The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.


HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22
News | January 12, 2023

HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22

The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management


Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer
News | January 12, 2023

Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer

Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies


Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain
News | January 10, 2023

Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain

NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)